L3VLUP
ProSign in

NVO · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVOJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVO
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterNVOJNJ
Q3 20207 holders, $2.2bn30 holders, $26.2bn
Q4 20205 holders, $2.0bn32 holders, $26.6bn
Q1 20214 holders, $1.8bn31 holders, $25.3bn
Q2 20215 holders, $2.2bn37 holders, $25.6bn
Q3 20217 holders, $2.4bn40 holders, $24.1bn
Q4 20216 holders, $2.5bn33 holders, $25.2bn
Q1 20227 holders, $2.4bn35 holders, $28.2bn
Q2 202210 holders, $2.5bn33 holders, $26.9bn
Q3 20227 holders, $1.8bn36 holders, $25.4bn
Q4 202212 holders, $3.1bn35 holders, $27.6bn
Q1 202314 holders, $3.8bn42 holders, $24.5bn
Q2 202317 holders, $4.3bn38 holders, $25.0bn
Q3 202320 holders, $5.6bn37 holders, $18.9bn
Q4 202323 holders, $6.0bn31 holders, $19.0bn
Q1 202417 holders, $7.3bn32 holders, $19.7bn
Q2 202424 holders, $8.7bn35 holders, $20.4bn
Q3 202423 holders, $6.5bn28 holders, $22.3bn
Q4 202421 holders, $4.3bn37 holders, $20.4bn
Q1 202518 holders, $2.8bn32 holders, $20.5bn
Q2 202515 holders, $2.4bn31 holders, $18.4bn
Q3 202515 holders, $1.6bn32 holders, $23.7bn
Q4 202512 holders, $1.6bn29 holders, $27.8bn
Q1 202617 holders, $2.9bn34 holders, $35.6bn
Q2 202615 holders, $3.0bn33 holders, $39.1bn
NVO

Novo-nordisk A S

Holders
23
Reported value
$6.0bn
Buyers
14
Sellers
8

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
31
Reported value
$19.0bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVO (13)

Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Capital World Investors, Coatue Management LLC, Holocene Advisors LP, Marshall Wace LLP, Millennium Management LLC, Moore Capital Management LP, Polen Capital Management LLC, Soros Fund Management LLC, Tiger Global Management LLC, Walleye Capital LLC

Only JNJ (21)

AllianceBernstein LP, AQR Capital Management LLC, Bridgewater Associates LP, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Quantbot Technologies LP, Squarepoint Ops LLC, Susquehanna International Group LLP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →